Equities analysts expect Dynavax Technologies Co. (NASDAQ:DVAX) to report earnings of ($0.58) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Dynavax Technologies’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.60). Dynavax Technologies reported earnings of ($0.38) per share in the same quarter last year, which would indicate a negative year over year growth rate of 52.6%. The company is expected to report its next earnings results after the market closes on Monday, November 5th.
According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.33). For the next year, analysts forecast that the company will report earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Dynavax Technologies.
A number of analysts have recently weighed in on the company. ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Cowen reissued a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, October 22nd. Royal Bank of Canada increased their price objective on Dynavax Technologies to $26.00 and gave the company an “outperform” rating in a research note on Monday, October 22nd. Cantor Fitzgerald upped their target price on Dynavax Technologies to $32.00 and gave the company an “overweight” rating in a report on Monday, October 22nd. Finally, BidaskClub upgraded Dynavax Technologies from a “strong sell” rating to a “sell” rating in a report on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Dynavax Technologies currently has an average rating of “Hold” and an average target price of $28.25.
Shares of NASDAQ:DVAX traded down $0.03 during trading on Wednesday, reaching $11.37. 6,069 shares of the company traded hands, compared to its average volume of 1,715,204. The firm has a market cap of $713.82 million, a PE ratio of -6.51 and a beta of 0.61. Dynavax Technologies has a 52-week low of $9.63 and a 52-week high of $23.85. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87.
Institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can raised its holdings in shares of Dynavax Technologies by 365.4% during the second quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 10,943 shares in the last quarter. Chicago Capital LLC raised its holdings in Dynavax Technologies by 48.3% in the second quarter. Chicago Capital LLC now owns 1,294,104 shares of the biopharmaceutical company’s stock worth $19,735,000 after purchasing an additional 421,446 shares in the last quarter. Creative Planning raised its holdings in Dynavax Technologies by 2.6% in the second quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock worth $3,585,000 after purchasing an additional 5,857 shares in the last quarter. Xact Kapitalforvaltning AB bought a new position in Dynavax Technologies in the first quarter worth $200,000. Finally, Tiverton Asset Management LLC bought a new position in Dynavax Technologies in the second quarter worth $184,000. Institutional investors own 81.48% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Read More: Dow Jones Industrial Average (DJIA)
Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.